Tuesday 25 October 2016

Market Misses Upside on Merck

Strong third-quarter results and better sales for cancer and hepatitis C drugs suggest Merck’s rise could continue.

from WSJ.com: Markets http://ift.tt/2eHZSCy
via https://ifttt.com/ IFTTT
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)